FIELD: biotechnology.
SUBSTANCE: disclosed is an antisense oligomer with length of 15 to 30 bases for skipping of 44 exon in a human dystrophin gene containing a nucleotide sequence selected from a group consisting of SEQ ID NO: 7, 55, 8, 9, 106 and 6. Disclosed is a pharmaceutical composition containing said oligomer. Disclosed is a method for treating muscular dystrophy involving administering to a patient suffering muscular dystrophy of said antisense oligomer or pharmaceutical composition.
EFFECT: invention can be used to produce a drug which induces high-efficiency exon skipping.
16 cl, 32 dwg, 7 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTISENSE NUCLEIC ACIDS | 2012 |
|
RU2619184C2 |
| ANTISENSE NUCLEIC ACIDS | 2015 |
|
RU2825834C2 |
| ANTISENSE NUCLEIC ACIDS | 2015 |
|
RU2702424C2 |
| ANTISENSE NUCLEIC ACID | 2016 |
|
RU2724554C2 |
| ANTISENSE NUCLEIC ACIDS | 2018 |
|
RU2681470C1 |
| ANTISENSE NUCLEIC ACIDS | 2012 |
|
RU2651468C1 |
| ANTISENSE NUCLEIC ACIDS | 2015 |
|
RU2730681C2 |
| ANTISENSE NUCLEIC ACIDS | 2011 |
|
RU2567664C2 |
| COMPOSITION CONTAINING ANTISENSE OLIGONUCLEOTIDE AND ITS USE FOR THE TREATMENT OF DUSCHENNE MUSCULAR DYSTROPHY | 2019 |
|
RU2799442C2 |
| MYOSTATIN SIGNAL INHIBITOR | 2019 |
|
RU2820270C2 |
